Frontlight ResearchEarly access
Taking people in United StatesPhase 4
Early Angiotensin II in the Emergency Department
Key facts
- Who runs it
- Brett A Faine
- Where
- Iowa City, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 20 people, planned
- Started
- 1 Apr 2025
- Expected to end
- 30 Jan 2027
- Type of study
- Interventional
- Treatments tested
- Angiotensin II Infusion
- Record updated
- 2 September 2026
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 12 criteriaShow less
Who can take part
- Age ≥18; and
- Requiring norepinephrine at a dose of 0.05-0.25 mcg/kg/min mcg/kg/minute despite adequate fluid resuscitation; and
- Receiving intravenous antibiotics or clinician's intention to administer antibiotics at the time of enrollment; and
- Can provide written informed consent (or legally authorized representative)
Who cannot take part
- Patients with hemorrhagic shock (e.g., actively receiving transfusion of packed red blood cells)
- Acute coronary syndrome
- Patients with a history of mesenteric ischemia
- Patients with a history of having an aortic dissection or abdominal aortic aneurysm
- Pre-existing thromboembolic disease or inability to tolerate pharmacologic VTE prophylaxis
- Cardiogenic shock
- Patients with an expected lifespan of <12 hours
- Active administration of two vasoactive agents before enrollment; and
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
This trial is currently available in United States.
- University of Iowa Hospitals and ClinicsIowa City, United StatesContact: Brett FaineTaking people
About the trial
What the trial wants to find out
This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
The group in the trial
- Angiotensin II InfusionTreatment being tested
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- ANGIOtensin II for Septic Shock in the Emergency Department: ANGIO-ED Study
- Criteria questions
- Built from NCT06693726, who can take part
- Record updated
- 2 September 2026